Investigational Cream Promising for Atopic Dermatitis

Share this content:
Investigational Cream Promising for Atopic Dermatitis
Investigational Cream Promising for Atopic Dermatitis

MONDAY, Jan. 14, 2019 (HealthDay News) -- Topical application of a transient receptor potential vanilloid subfamily, member 1 (TRPV1) antagonist may be an effective and safe treatment for patients with mild-to-moderate atopic dermatitis (AD), according to a phase IIb study published online Jan. 8 in the British Journal of Dermatology.

Y.W. Lee, from Konkuk University School of Medicine in Seoul, South Korea, and colleagues assessed the clinical efficacy and safety of PAC-14028, a TRPV1 antagonist, via topical application in 194 patients with mild-to-moderate AD. Participants were randomly assigned to receive either PAC-14028 cream 0.1 percent, 0.3 percent, or 1 percent or vehicle cream twice daily for eight weeks.

The researchers found that Investigator's Global Assessment (IGA) success rates at week 8 were 14.58 percent for vehicle cream, 42.55 percent for 0.1 percent PAC-14028 cream, 38.3 percent for 0.3 percent PAC-14028 cream, and 57.45 percent for 1 percent PAC-14028 cream. Statistically significant differences were noted between the vehicle and treatment groups in the IGA success rates with two-grade improvement in particular. In addition, there was a trend toward improvement in the Scoring of Atopic Dermatitis index, Eczema Area and Severity Index 75/90, sleep disturbance score, and pruritus visual analogue scale. The researchers reported no significant safety issues.

"PAC-14028 cream is a promising new treatment option for patients with mild-to-moderate AD based on the favorable tolerability profile and the improved efficacy in treating AD observed in the present study," the authors write.

Several authors disclosed financial ties to pharmaceutical and personal care companies, including AmorePacific Corp., which manufactures PAC-14028 and funded the study.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA: Gout Drug Uloric Increases Risk of Death

FDA: Gout Drug Uloric Increases Risk of Death

Medication is associated with increased risk of heart-related death and death from all causes

Since Early 2000s, Overdose Death Rates Are Highest in U.S.

Since Early 2000s, Overdose Death Rates Are Highest ...

U.S. was not an outlier in terms of drug overdose mortality prior to the early 2000s

National Health Spending Set to Increase 5.5 Percent Annually

National Health Spending Set to Increase 5.5 Percent ...

Long-observed demographic and economic factors expected to drive growth in health spending

is free, fast, and customized just for you!




Already a member?

Sign In Now »